Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMRA NASDAQ:EVLO NASDAQ:GNCAQ NASDAQ:NMTR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMRAComera Life Sciences$0.00$0.00$0.00▼$0.03$6K1.286,565 shsN/AEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.02$9K0.7910,810 shs60 shsGNCAQGenocea Biosciences$0.00$0.00▼$0.00$6K1.741,863 shsN/ANMTR9 Meters Biopharma$0.00$0.07▼$6.56$3K1.36315,915 shs52,593 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMRAComera Life Sciences0.00%0.00%0.00%+100.00%-99.10%EVLOEvelo Biosciences0.00%0.00%0.00%+66.67%+400.00%GNCAQGenocea Biosciences0.00%0.00%0.00%0.00%0.00%NMTR9 Meters Biopharma0.00%-99.72%-99.72%-99.72%-81.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMRAComera Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AGNCAQGenocea BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMRAComera Life Sciences 0.00N/AN/AN/AEVLOEvelo Biosciences 0.00N/AN/AN/AGNCAQGenocea Biosciences 0.00N/AN/AN/ANMTR9 Meters Biopharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMRAComera Life Sciences$1.00M0.01N/AN/AN/A∞EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AGNCAQGenocea BiosciencesN/AN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMRAComera Life Sciences-$18MN/A0.00∞N/AN/AN/AN/AN/AEVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/AN/AGNCAQGenocea BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/ANMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMRAComera Life SciencesN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AGNCAQGenocea BiosciencesN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMRAComera Life SciencesN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AGNCAQGenocea BiosciencesN/AN/AN/ANMTR9 Meters BiopharmaN/A0.590.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMRAComera Life SciencesN/AEVLOEvelo Biosciences0.31%GNCAQGenocea BiosciencesN/ANMTR9 Meters Biopharma22.34%Insider OwnershipCompanyInsider OwnershipCMRAComera Life Sciences8.90%EVLOEvelo Biosciences1.02%GNCAQGenocea Biosciences1.61%NMTR9 Meters Biopharma2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMRAComera Life Sciences230.74 million28.00 millionNot OptionableEVLOEvelo Biosciences12018.98 million18.79 millionNo DataGNCAQGenocea Biosciences7058.73 millionN/ANot OptionableNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataNMTR, EVLO, CMRA, and GNCAQ HeadlinesRecent News About These CompaniesWhat is a prepayment meter?August 24, 2024 | uswitch.comUAfter coeliac fail, 9 Meters plots phase 3 in short bowel syndromeJuly 28, 2024 | pharmaphorum.comPEnergy firms likely to miss smart meter deadline, warns Which?December 14, 2023 | bbc.comBDeal reached to sell some assets of bankrupt Raleigh firmNovember 8, 2023 | bizjournals.com9 Meters Biopharma, Inc. (NMTRQ)November 7, 2023 | finance.yahoo.comTRACK AND FIELD/ Yamagata sets Japan record in 100-meter sprint with 9.95 secondsOctober 28, 2023 | asahi.comA9 Meters Biopharma Inc (NMTRQ)October 17, 2023 | investing.comVintage Meters Reborn As Steam Punk ClockOctober 10, 2023 | hackaday.comH9 Meters Biopharma (OTC: NMTR.Q)August 16, 2023 | fool.comInsider Sale Alert: 9 Meters Biopharma Inc. [NMTR] – Is it Time to sell?July 25, 2023 | knoxdaily.comK9 Meters Biopharma Inc. [NASDAQ: NMTR] Sees Decrease in Stock ValueJuly 21, 2023 | knoxdaily.comKRaleigh firm joins worrying trend of bankruptcies for drugmakersJuly 18, 2023 | bizjournals.comDrug developer 9 Meters Biopharma files for bankruptcy protectionJuly 18, 2023 | reuters.comWhy Are 9 Meters Biopharma Shares Nosediving Today?July 18, 2023 | finance.yahoo.comExamining the Potential Price Growth of 9 Meters Biopharma Inc. (NMTR)July 18, 2023 | knoxdaily.comKTemperato resigns as CEO of Raleigh drugmakerMay 30, 2023 | bizjournals.com9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel SyndromeMay 30, 2023 | finance.yahoo.com9 Meters Biopharma (NASDAQ: NMTR)May 27, 2023 | fool.comNMTR - 9 Meters Biopharma, Inc.May 25, 2023 | uk.finance.yahoo.comCitigroup Maintains 9 Meters Biopharma (NMTR) Neutral RecommendationMay 19, 2023 | msn.comMedia Sentiment Over TimeNMTR, EVLO, CMRA, and GNCAQ Company DescriptionsComera Life Sciences NASDAQ:CMRA$0.0002 0.00 (0.00%) As of 08/8/2025Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.Evelo Biosciences NASDAQ:EVLO$0.0005 0.00 (0.00%) As of 08/8/2025Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Genocea Biosciences NASDAQ:GNCAQGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
